vudalimab + cabazitaxel + docetaxel

**Vudalimab + cabazitaxel + docetaxel** is an investigational combination therapy being studied primarily for advanced nonsquamous non-small cell lung cancer (NSCLC). **Vudalimab (XmAb20717)** is a bispecific monoclonal antibody that targets both **Programmed cell death protein 1 (PD-1)** and **Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)**, acting as a dual immune checkpoint inhibitor with the goal of enhancing T-cell mediated anti-tumor immunity. **Cabazitaxel** and **docetaxel** are cytotoxic chemotherapeutic agents in the taxane class, both functioning as microtubule inhibitors to block cell division and promote tumor cell death. This therapeutic combination leverages immune checkpoint blockade with the cytotoxic effects of chemotherapeutic agents, aiming to increase overall anti-tumor efficacy through complementary mechanisms: immune activation and direct tumor cell killing[1][3].